Abstract Purpose: To evaluated the clinical features, prognosis and complications of 20 cases of diagnosed with cytomegalovirus anterior uveitis (CMV AU) an and who used oral valganciclovir (VGV). Methods: Medical records of patients with CMV AU were reviewed and patients undergoe complete ophthalmologic examinations. Results: Six patients (30%) were female and 14 patients (70%) were male. The mean age of admitted to Uvea-Behçet unit was 41.0 ± 3.2 (range, 19–66) years. Acute type CMV AU was diagnosed in 6 (30%) patients and chronic type in 14 (70%) patients; 2 (10%) patients were Fuch’s type and 12 (60%) patients were other type. The mean intraocular pressure (IOP) before treatment was 36.4 ± 19.5 (13–75) mm Hg. The pupils persists round and vitritis, prominent posterior synechiae and heterochromia did not presented in any patients. Sectorial superficial stromal iris atrophy were seen in 4 (20%) patients. The average duration of oral VGV treatment was 13.4 ± 1.3 (range, 6–25) months. In 12 (60%) patients who were monitored for remission after VGV stopped, no recurrence was observed. The average duration of remission after for 12 (60%) patients was 36.1 ± 9 (range, 18–102) months. The mean IOP after treatment was 9.9 ± 3.3 (range, 7–15) mm Hg. Conclusions: Oral VGV therapy is an effective and safe treatment for CMV AU, an effective prevention against glaucoma is early detection of CMV AU and early access to VGV treatment.